Last updated on November 2017

Clinical trial for Patients with leukemia or lymphoma MI-CP204 (The Blood Cancer Study)

Other Details:

The investigational medication is an antibody that sticks to CD19, a protein that is commonly found on cancerous B-cells. CD19 is different from the protein (CD20) that rituximab targets. MI-CP204 (The Blood Cancer Study) is not a new study. It has been running for several years and 91 patients have already been enrolled and treated with the investigational medication. Early results seem promising and researchers now want to look at new dosing schedules for the investigational medication and also to study what happens when the investigational medication is given in combination with rituximab. As part of the study, the doctor will perform a number of tests and assessments during your visits to monitor your health and progress.

This study has an online pre-screener.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.